-DOCSTART- -X- O
OBJECTIVES -X- _ O
: -X- _ O
Skin -X- _ O
biopsies -X- _ O
from -X- _ O
local -X- _ O
sites -X- _ O
of -X- _ O
herpes -X- _ O
simplex -X- _ O
virus -X- _ O
2 -X- _ O
( -X- _ O
HSV-2 -X- _ O
) -X- _ O
-induced -X- _ O
ulcers -X- _ O
can -X- _ O
show -X- _ O
infiltrates -X- _ O
of -X- _ O
inflammatory -X- _ O
cells -X- _ O
several -X- _ O
months -X- _ O
after -X- _ O
macroscopic -X- _ O
healing. -X- _ O
We -X- _ O
hypothesise -X- _ O
that -X- _ O
foreskin -X- _ B-Patient
tissue -X- _ I-Patient
samples -X- _ I-Patient
of -X- _ I-Patient
asymptomatic -X- _ I-Patient
HSV-2 -X- _ I-Patient
seropositive -X- _ I-Patient
men -X- _ I-Patient
had -X- _ O
remaining -X- _ O
signs -X- _ O
of -X- _ O
inflammation -X- _ O
at -X- _ O
the -X- _ O
molecular -X- _ O
level. -X- _ O
Even -X- _ O
in -X- _ O
the -X- _ O
absence -X- _ O
of -X- _ O
clinical -X- _ O
lesions -X- _ O
, -X- _ O
genital -X- _ O
inflammation -X- _ O
may -X- _ O
contribute -X- _ O
to -X- _ O
increased -X- _ O
HIV -X- _ O
susceptibility -X- _ O
on -X- _ O
sexual -X- _ O
exposure -X- _ O
to -X- _ O
the -X- _ O
virus. -X- _ O
SETTING -X- _ O
: -X- _ O
Foreskin -X- _ B-Patient
tissue -X- _ I-Patient
samples -X- _ I-Patient
were -X- _ I-Patient
collected -X- _ I-Patient
from -X- _ I-Patient
men -X- _ I-Patient
undergoing -X- _ O
elective -X- _ O
circumcision -X- _ O
in -X- _ O
Kisumu -X- _ O
, -X- _ O
Kenya. -X- _ O
PARTICIPANTS -X- _ O
: -X- _ O
The -X- _ O
foreskin -X- _ O
tissue -X- _ O
samples -X- _ O
( -X- _ O
n=86 -X- _ O
) -X- _ O
were -X- _ O
stratified -X- _ O
into -X- _ O
study -X- _ O
groups -X- _ O
based -X- _ O
on -X- _ O
HSV-2 -X- _ O
serology -X- _ O
and -X- _ O
assessed -X- _ O
for -X- _ O
mRNA -X- _ O
expression -X- _ O
of -X- _ O
inflammatory -X- _ O
markers. -X- _ O
Markers -X- _ O
of -X- _ O
interest -X- _ O
were -X- _ O
further -X- _ O
assessed -X- _ O
by -X- _ O
immunohistochemical -X- _ O
staining -X- _ O
within -X- _ O
the -X- _ O
tissue -X- _ O
samples. -X- _ O
RESULTS -X- _ O
: -X- _ O
The -X- _ B-Outcome
two -X- _ I-Outcome
study -X- _ I-Outcome
groups -X- _ I-Outcome
had -X- _ I-Outcome
comparable -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
molecular -X- _ I-Outcome
markers -X- _ I-Outcome
( -X- _ I-Outcome
CD3 -X- _ I-Outcome
, -X- _ I-Outcome
CD4 -X- _ I-Outcome
, -X- _ I-Outcome
CD8 -X- _ I-Outcome
, -X- _ I-Outcome
CD69 -X- _ I-Outcome
, -X- _ I-Outcome
CCR5 -X- _ I-Outcome
, -X- _ I-Outcome
HLA-DR -X- _ I-Outcome
, -X- _ I-Outcome
Langerin -X- _ I-Outcome
, -X- _ I-Outcome
DC-SIGN -X- _ I-Outcome
, -X- _ I-Outcome
Mannose -X- _ I-Outcome
Receptor -X- _ I-Outcome
1 -X- _ I-Outcome
, -X- _ I-Outcome
IL-1 -X- _ I-Outcome
, -X- _ I-Outcome
IL-6 -X- _ I-Outcome
, -X- _ I-Outcome
TNF-α -X- _ I-Outcome
, -X- _ I-Outcome
β7 -X- _ I-Outcome
, -X- _ I-Outcome
IgA -X- _ I-Outcome
, -X- _ I-Outcome
IFN-α -X- _ I-Outcome
, -X- _ I-Outcome
CCL5 -X- _ I-Outcome
, -X- _ I-Outcome
E- -X- _ I-Outcome
cadherin -X- _ I-Outcome
, -X- _ I-Outcome
ZO-1 -X- _ I-Outcome
and -X- _ I-Outcome
occludin -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
except -X- _ I-Outcome
for -X- _ I-Outcome
lower -X- _ I-Outcome
mRNA -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
the -X- _ I-Outcome
epithelial -X- _ I-Outcome
junction -X- _ I-Outcome
protein -X- _ I-Outcome
claudin-1 -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
HSV-2 -X- _ I-Outcome
seropositive -X- _ I-Outcome
group -X- _ I-Outcome
( -X- _ I-Outcome
p=0.008 -X- _ I-Outcome
) -X- _ I-Outcome
. -X- _ I-Outcome
Although -X- _ I-Outcome
mRNA -X- _ I-Outcome
levels -X- _ I-Outcome
of -X- _ I-Outcome
claudin-1 -X- _ I-Outcome
were -X- _ I-Outcome
lower -X- _ I-Outcome
in -X- _ I-Outcome
HSV-2 -X- _ I-Outcome
seropositive -X- _ I-Outcome
individuals -X- _ I-Outcome
, -X- _ I-Outcome
the -X- _ I-Outcome
corresponding -X- _ I-Outcome
protein -X- _ I-Outcome
could -X- _ I-Outcome
be -X- _ I-Outcome
visualised -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
foreskin -X- _ I-Outcome
epithelium -X- _ I-Outcome
of -X- _ I-Outcome
all -X- _ I-Outcome
samples -X- _ I-Outcome
tested. -X- _ I-Outcome
CONCLUSIONS -X- _ O
: -X- _ O
Whereas -X- _ O
no -X- _ B-Outcome
general -X- _ I-Outcome
inflammation -X- _ I-Outcome
was -X- _ I-Outcome
demonstrated -X- _ I-Outcome
in -X- _ I-Outcome
the -X- _ I-Outcome
foreskin -X- _ I-Outcome
of -X- _ I-Outcome
asymptomatic -X- _ I-Outcome
HSV-2 -X- _ I-Outcome
seropositive -X- _ I-Outcome
individuals -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
decreased -X- _ I-Outcome
expression -X- _ I-Outcome
of -X- _ I-Outcome
claudin-1 -X- _ I-Outcome
indicates -X- _ I-Outcome
a -X- _ I-Outcome
less -X- _ I-Outcome
robust -X- _ I-Outcome
genital -X- _ I-Outcome
epithelial -X- _ I-Outcome
barrier. -X- _ I-Outcome
An -X- _ I-Outcome
intact -X- _ I-Outcome
epithelial -X- _ I-Outcome
barrier -X- _ I-Outcome
is -X- _ I-Outcome
essential -X- _ I-Outcome
for -X- _ I-Outcome
blocking -X- _ I-Outcome
mucosal -X- _ I-Outcome
entry -X- _ I-Outcome
of -X- _ I-Outcome
genital -X- _ I-Outcome
infections -X- _ I-Outcome
, -X- _ I-Outcome
including -X- _ I-Outcome
HIV -X- _ I-Outcome
. -X- _ O

